GDRX GoodRx Holdings

GoodRx Releases Second Quarter 2021 Financial Results

GoodRx Releases Second Quarter 2021 Financial Results

SANTA MONICA, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: GDRX), America’s leading resource for healthcare savings, has released its second quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at .

GoodRx management will host a conference call and webcast today at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook. Today’s conference call and webcast will be extended to feature a presentation on pharma manufacturer solutions.

Second Quarter 2021 Results Conference Call

 Date:Thursday, August 12, 2021
 Time:5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time
 Webcast: (live and replay)
 Dial-in number:(833) 614-1447



Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at for at least 30 days.

About GoodRx

GoodRx helps Americans get the healthcare they need at a price they can afford. As America’s leading resource for healthcare savings, GoodRx connects consumers with affordable and convenient prescriptions and medical care, including telehealth, mail order prescriptions, doctor visits, and lab tests. We have helped Americans save over $30 billion since 2011 and we are one of the most downloaded medical apps over the past decade.

Investor Contact

GoodRx

Whitney Notaro

Press Contact

GoodRx

Lauren Casparis

 



EN
12/08/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GoodRx Holdings

GoodRx, Inc.: Update to credit analysis following refinancing

Our credit view of this issuer reflects its moderate financial leverage on a gross basis, constrained by its high dependence on PBM operating model.

Moody's Ratings affirms GoodRx's B1 CFR, assigns B1 rating to proposed...

Moody's Ratings (Moody's) affirmed the ratings of GoodRx, Inc. ("GoodRx"), including its B1 Corporate Family Rating ("CFR"), B1-PD Probability of Default Rating ("PDR"), and B1 rating on the backed senior secured first lien revolving credit facility. Concurrently, Moody's assigned a B1 rating to Goo...

GoodRx, Inc.: Update to credit analysis following refinancing of capit...

Our credit view of this issuer reflects its moderate financial leverage on a gross basis, constrained by its high dependence on PBM operating model.

Moody's affirms GoodRx's B1 CFR, assigns B1 rating to new bank credit ...

Moody's Investors Service (Moody's) affirmed the ratings of GoodRx, Inc. ("GoodRx"), including the B1 Corporate Family Rating (CFR) and B1-PD Probability of Default Rating (PDR). Concurrently, Moody's assigned a B1 rating to the new 7-year backed senior secured first lien term loan B and to the newl...

GoodRx, Inc.: Update to credit analysis

Our credit view of this issuer reflects its moderate financial leverage on a gross basis, constrained by its high dependence on PBM operating model.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch